<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02434770</url>
  </required_header>
  <id_info>
    <org_study_id>VAC-015</org_study_id>
    <nct_id>NCT02434770</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis Vaccine</brief_title>
  <official_title>A Phase III Single-blind, Randomized, Controlled Study in Healthy Kenyan Infants to Assess the Immunogenicity and Safety of Beijing TiantanBio Liquid Bivalent Oral Poliomyelitis Vaccine (bOPV) in Comparison to a WHO Prequalified Comparator bOPV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Bio-Institute Biological Products Co., Ltd., formerly Beijing TiantanBio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PATH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study will be to evaluate whether a bivalent oral polio vaccine (bOPV)
      manufactured by Beijing Bio-Institute Biological Products Co., Ltd (BBIBP) has a similar
      immunogenicity profile to a WHO prequalified bOPV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BBIBP has been one of the two suppliers of trivalent oral polio vaccine (tOPV) in China since
      1985, with control of polio in China evidence of the effectiveness of its vaccine. The
      company plans to introduce a liquid formulation of bOPV (types 1 and 3) to meet increasing
      global demand with the phasing-out of tOPV. The proposed study is intended to provide data
      sufficient to obtain World Heath Organization (WHO) prequalification for the BBIBP bOPV, thus
      making the vaccine available to help meet global demand.

      Infants were enrolled and randomized prior to the birth dose of bOPV. The first dose of study
      vaccine was administered during the first two weeks of life and then co-administered with the
      primary Expanded Programme on Immunization (EPI) series vaccines in Kenya at 6, 10 and 14
      weeks of age. The Kenya EPI schedule includes the following additional vaccines:

        -  Bacille Calmette-Guérin Vaccine (BCG) at birth

        -  Diphtheria and Tetanus Toxoid with Whole Cell Pertussis, Haemophilus influenzae Type V
           vaccine (Hib), and Hepatitis B Vaccine (DTwPHibHep) at 6, 10, 14 weeks;

        -  Pneumococcal Conjugate vaccine (PCV) at 6, 10, 14 weeks

        -  Rotavirus vaccine (Rotarix) at 6, 10 weeks
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">June 17, 2016</completion_date>
  <primary_completion_date type="Actual">June 17, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing Any Systemic Reactogenicity, by Maximum Severity</measure>
    <time_frame>7 days after each vaccination (Weeks 0, 6, 10, and 14)</time_frame>
    <description>Solicited systemic reactogenicity events evaluated during the week after each vaccination included fever, vomiting, diarrhea, decreased appetite/ poor feeding, irritability, and decreased activity. Reactions were recorded by participant's parents via memory aid. Each event was graded as:
Mild (Grade 1): No or minimal interference with usual activities; no medical intervention/therapy required, Moderate (Grade 2): Greater than minimal interference with usual activities; no or minimal medical intervention/therapy required, Severe (Grade 3): Marked limitation in ability to perform usual activities; medical intervention/therapy required, or Potentially life-threatening (Grade 4): Inability to perform basic functions OR Medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death.
The overall number of participants who experienced any systemic reaction is reported. Grades are based on maximum severity per participant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing Adverse Events</measure>
    <time_frame>From the time of the first vaccination through 28 days after each vaccination (up to Day 126).</time_frame>
    <description>Adverse events were graded as mild (Grade 1 = No or minimal interference with usual activities; no medical intervention/therapy required), moderate (Grade 2 = Greater than minimal interference with usual activities; no or minimal medical intervention/therapy required), severe (Grade 3 = Marked limitation in ability to perform usual activities; medical intervention/therapy required), or potentially life-threatening (Grade 4 = Inability to perform basic functions OR Medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death).
The overall number of participants who experienced any adverse event is reported. Grades are based on maximum severity per participant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-polio Neutralizing Antibody Geometric Mean Titers (GMT): Serotype 1</measure>
    <time_frame>Screening and 4 weeks post vaccination 4 (Week 18)</time_frame>
    <description>The assays for determination of anti-poliovirus neutralizing antibodies at the National Institutes for Food and Drug Control (NIFDC) were validated.
Anti-polio antibody titer four weeks after the fourth vaccination was adjusted for the decrease in maternal antibodies based on a half-life of 28 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-polio Neutralizing Antibody Geometric Mean Titers: Serotype 3</measure>
    <time_frame>Screening and 4 weeks post vaccination 4 (Week 18)</time_frame>
    <description>The assays for determination of anti-poliovirus neutralizing antibodies at the National Institutes for Food and Drug Control (NIFDC) were validated.
Anti-polio antibody titer four weeks after the fourth vaccination was adjusted for the decrease in maternal antibodies based on a half-life of 28 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Infants With Serotype-specific Anti-polio Neutralizing Antibody Seroconversion 4 Weeks After Last Dose</measure>
    <time_frame>4 weeks post vaccination 4 (Week 18)</time_frame>
    <description>The assays for determination of anti-poliovirus neutralizing antibodies at the National Institutes for Food and Drug Control (NIFDC) were validated.
Seroconversion was defined as a titer ≥ 1:8 if seronegative at screening, otherwise a ≥ 4-fold increase in adjusted titers (i.e., adjusted for the decay in maternal antibodies, based on a half life of 28 days).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-hepatitis B Surface Antigen (HBsAg) Geometric Mean Titers</measure>
    <time_frame>4 weeks post vaccination 4 (Week 18)</time_frame>
    <description>Anti-HBsAg titers were measured to assess the impact of concomitant administration of BBIBP liquid bOPV on immune responses to other Expanded Programme on Immunization (EPI) vaccines in comparison to that of the WHO pre-qualified bOPV, 4 weeks after the fourth vaccination.
The enzyme-linked immunosorbent assay (ELISA) assays for serum antibodies to HBsAg were performed at the Children's Hospital Medical Center (CCHMC). The HBsAb assay was a qualified assay using a kit from BioRad.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants With Anti-hepatitis B Surface Antigen (HBsAg) Seroprotection</measure>
    <time_frame>28 days after vaccination 4</time_frame>
    <description>Seroprotection was defined as a HBsAg titer ≥ 1:10 The ELISA assays for serum antibodies to HBsAg were performed at the Children's Hospital Medical Center (CCHMC). The HBsAb assay was a qualified assay using a kit from BioRad.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Rotavirus Immunoglobulin A (IgA) Geometric Mean Titers</measure>
    <time_frame>4 weeks post vaccination 4 (Week 18)</time_frame>
    <description>Anti-rotavirus immunoglobulin A titers were measured to assess the impact of concomitant administration of BBIBP liquid bOPV on immune responses to other Expanded Programme on Immunization (EPI) vaccines in comparison to that of the WHO pre-qualified bOPV, 4 weeks after the fourth vaccination.
The ELISA assay for antibodies to rotavirus was performed at the Children's Hospital Medical Center (CCHMC) using a validated in-house assay.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">750</enrollment>
  <condition>Poliomyelitis</condition>
  <arm_group>
    <arm_group_label>BBIBP bOPV Lot 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 1, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BBIBP bOPV Lot 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 2, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BioFarma bOPV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infants received 2 drops of WHO prequalified liquid bivalent oral polio vaccine manufactured by BioFarma, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BBIBP Bivalent Oral Poliomyelitis Vaccine Lot 1</intervention_name>
    <description>Each dose of bOPV (2 drops, 0.1 ml) contains attenuated Sabin strains of poliovirus serotypes 1 and 3, with at least 10^6 cell culture infectious dose 50% (CCID50)/dose and 10^5.8 CCID50/dose, respectively.</description>
    <arm_group_label>BBIBP bOPV Lot 1</arm_group_label>
    <other_name>Poliomyelitis (Live) Vaccine Type I Type III (Human Diploid Cell), Oral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BBIBP Bivalent Oral Poliomyelitis Vaccine Lot 2</intervention_name>
    <description>Each dose of bOPV (2 drops, 0.1 ml) contains types 1 and 3 attenuated polioviruses (Sabin), with at least 10^6 CCID50/dose and 10^5.8 CCID50/dose, respectively.</description>
    <arm_group_label>BBIBP bOPV Lot 2</arm_group_label>
    <other_name>Poliomyelitis (Live) Vaccine Type I Type III (Human Diploid Cell), Oral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BioFarma Bivalent Oral Poliomyelitis Vaccine</intervention_name>
    <description>Each dose of the WHO prequalified Bio Farma bOPV (2 drops, 0.1 ml) contains attenuated Sabin strains of poliovirus serotypes 1 and 3, with at least 10^6 and 10^5.8 infective units per dose, respectively.</description>
    <arm_group_label>BioFarma bOPV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, full-term infants, as established by medical history and clinical examination
             before entering into the study.

          -  Parents willing to provide written informed consent.

          -  Age: infants less than 2 weeks of age at the time of enrollment (from the 1st through
             the 14th day of life, inclusive)

        Exclusion Criteria:

          -  Birth weight (as documented at first medical contact) less than 2.5 kg

          -  Presence of diarrhea or vomiting in the previous 24 hours or on the day of enrollment
             (temporary exclusion)

          -  Presence of fever (&gt; 37.5°C) on the day of enrollment (temporary exclusion)

          -  Acute disease at the time of enrollment (temporary exclusion)

          -  Significant malnutrition as per Investigator's judgment

          -  Concurrent participation in another clinical study at any time during the study period
             in which the infant will be exposed to an investigational or a non-investigational
             product

          -  Presence of any significant systemic disorder (cardiovascular, pulmonary, hepatic,
             renal, gastrointestinal, hematological, endocrine, immunological, dermatological,
             neurological, cancer or autoimmune disease) as determined by medical history and/or
             physical examination which would compromise the child's health or is likely to result
             in non-conformance to the protocol

          -  Known or suspected impairment of immunological function (including human
             immunodeficiency virus [HIV] exposure) based on medical history and physical
             examination

          -  Previous receipt of polio virus vaccine

          -  Household contact with a known immunosuppressed individual

          -  Unwillingness or inability of parents for active follow-up by the study staff

          -  History of any neurological disorders or seizures

          -  Any medical condition that, in the judgment of the investigator, would interfere with
             or serve as a contraindication to protocol adherence or a participant's ability to
             give informed consent

          -  Maternal HIV infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>14 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Cowden, MD, MSPH</last_name>
    <role>Study Chair</role>
    <affiliation>US Army Medical Research Unit-Kenya</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kenya Medical Research Institute/Walter Reed Project</name>
      <address>
        <city>Kisumu</city>
        <state>Nyanza</state>
        <zip>PO Box 54-40100</zip>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kenya Medical Research Institute (KEMRI)/Walter Reed Project</name>
      <address>
        <city>Kericho</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 30, 2015</study_first_submitted>
  <study_first_submitted_qc>May 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2015</study_first_posted>
  <results_first_submitted>September 14, 2018</results_first_submitted>
  <results_first_submitted_qc>February 25, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 10, 2020</results_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the communities in the vicinity of the study clinics (KEMRI/Walter Reed Project Kombewa Clinical Research Center and Obama Children’s Hospital in Kisumu and at the Kenya Medical Research Institute/Walter Reed Project in Kericho, Kenya).</recruitment_details>
      <pre_assignment_details>Infants were enrolled prior to receipt of the birth dose of bivalent oral poliomyelitis vaccine (bOPV} and were were allocated to 1 of 3 arms:
Beijing Bio-Institute Biological Products Co., Ltd. (BBIBP) liquid bOPV Lot 1;
BBIBP liquid bOPV Lot 2; and
World Health Organization (WHO) prequalified comparator bOPV (BioFarma).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>BBIBP bOPV Lot 1</title>
          <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 1, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
        </group>
        <group group_id="P2">
          <title>BBIBP bOPV Lot 2</title>
          <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 2, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
        </group>
        <group group_id="P3">
          <title>BioFarma bOPV</title>
          <description>Infants received 2 drops of WHO prequalified liquid bivalent oral polio vaccine manufactured by BioFarma, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Week 1 to Week 18</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="250"/>
                <participants group_id="P2" count="250"/>
                <participants group_id="P3" count="250"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Vaccination</title>
              <participants_list>
                <participants group_id="P1" count="249"/>
                <participants group_id="P2" count="250"/>
                <participants group_id="P3" count="250"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="235"/>
                <participants group_id="P2" count="228"/>
                <participants group_id="P3" count="233"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Received Non-study Polio Vaccine</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relocated Out of Study Area</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Week 18 to Week</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="235"/>
                <participants group_id="P2" count="228"/>
                <participants group_id="P3" count="233"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="227"/>
                <participants group_id="P2" count="220"/>
                <participants group_id="P3" count="227"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Received Non-study Polio Vaccine</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BBIBP bOPV Lot 1</title>
          <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 1, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
        </group>
        <group group_id="B2">
          <title>BBIBP bOPV Lot 2</title>
          <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 2, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
        </group>
        <group group_id="B3">
          <title>BioFarma bOPV</title>
          <description>Infants received 2 drops of WHO prequalified liquid bivalent oral polio vaccine manufactured by BioFarma, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="249"/>
            <count group_id="B2" value="250"/>
            <count group_id="B3" value="250"/>
            <count group_id="B4" value="749"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.0" lower_limit="0" upper_limit="14"/>
                    <measurement group_id="B2" value="1.0" lower_limit="0" upper_limit="13"/>
                    <measurement group_id="B3" value="1.0" lower_limit="0" upper_limit="14"/>
                    <measurement group_id="B4" value="1.0" lower_limit="0" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="121"/>
                    <measurement group_id="B4" value="355"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="129"/>
                    <measurement group_id="B4" value="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="248"/>
                    <measurement group_id="B2" value="250"/>
                    <measurement group_id="B3" value="250"/>
                    <measurement group_id="B4" value="748"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Kenya</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="249"/>
                    <measurement group_id="B2" value="250"/>
                    <measurement group_id="B3" value="250"/>
                    <measurement group_id="B4" value="749"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Length at Enrollment</title>
          <units>centimeters</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.5" lower_limit="45.0" upper_limit="55.0"/>
                    <measurement group_id="B2" value="49.5" lower_limit="44.0" upper_limit="62.0"/>
                    <measurement group_id="B3" value="49.0" lower_limit="37.0" upper_limit="54.5"/>
                    <measurement group_id="B4" value="49.5" lower_limit="37.0" upper_limit="62.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight at Enrollment</title>
          <units>kilograms</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.2" lower_limit="2.4" upper_limit="4.5"/>
                    <measurement group_id="B2" value="3.1" lower_limit="2.4" upper_limit="4.5"/>
                    <measurement group_id="B3" value="3.1" lower_limit="2.3" upper_limit="4.9"/>
                    <measurement group_id="B4" value="3.1" lower_limit="2.3" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI) at Enrollment</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.9" lower_limit="9.9" upper_limit="18.0"/>
                    <measurement group_id="B2" value="13.0" lower_limit="8.1" upper_limit="17.5"/>
                    <measurement group_id="B3" value="12.8" lower_limit="10.0" upper_limit="25.6"/>
                    <measurement group_id="B4" value="12.9" lower_limit="8.1" upper_limit="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Any Systemic Reactogenicity, by Maximum Severity</title>
        <description>Solicited systemic reactogenicity events evaluated during the week after each vaccination included fever, vomiting, diarrhea, decreased appetite/ poor feeding, irritability, and decreased activity. Reactions were recorded by participant's parents via memory aid. Each event was graded as:
Mild (Grade 1): No or minimal interference with usual activities; no medical intervention/therapy required, Moderate (Grade 2): Greater than minimal interference with usual activities; no or minimal medical intervention/therapy required, Severe (Grade 3): Marked limitation in ability to perform usual activities; medical intervention/therapy required, or Potentially life-threatening (Grade 4): Inability to perform basic functions OR Medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death.
The overall number of participants who experienced any systemic reaction is reported. Grades are based on maximum severity per participant.</description>
        <time_frame>7 days after each vaccination (Weeks 0, 6, 10, and 14)</time_frame>
        <population>The safety population included all enrolled participants who had safety data available, assigned according to the actual treatment received at Day 0.</population>
        <group_list>
          <group group_id="O1">
            <title>BBIBP bOPV Lot 1</title>
            <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 1, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>BBIBP bOPV Lot 2</title>
            <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 2, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
          <group group_id="O3">
            <title>BioFarma bOPV</title>
            <description>Infants received 2 drops of WHO prequalified liquid bivalent oral polio vaccine manufactured by BioFarma, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Any Systemic Reactogenicity, by Maximum Severity</title>
          <description>Solicited systemic reactogenicity events evaluated during the week after each vaccination included fever, vomiting, diarrhea, decreased appetite/ poor feeding, irritability, and decreased activity. Reactions were recorded by participant's parents via memory aid. Each event was graded as:
Mild (Grade 1): No or minimal interference with usual activities; no medical intervention/therapy required, Moderate (Grade 2): Greater than minimal interference with usual activities; no or minimal medical intervention/therapy required, Severe (Grade 3): Marked limitation in ability to perform usual activities; medical intervention/therapy required, or Potentially life-threatening (Grade 4): Inability to perform basic functions OR Medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death.
The overall number of participants who experienced any systemic reaction is reported. Grades are based on maximum severity per participant.</description>
          <population>The safety population included all enrolled participants who had safety data available, assigned according to the actual treatment received at Day 0.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="250"/>
                <count group_id="O3" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any systemic reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187"/>
                    <measurement group_id="O2" value="179"/>
                    <measurement group_id="O3" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="139"/>
                    <measurement group_id="O3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Adverse Events</title>
        <description>Adverse events were graded as mild (Grade 1 = No or minimal interference with usual activities; no medical intervention/therapy required), moderate (Grade 2 = Greater than minimal interference with usual activities; no or minimal medical intervention/therapy required), severe (Grade 3 = Marked limitation in ability to perform usual activities; medical intervention/therapy required), or potentially life-threatening (Grade 4 = Inability to perform basic functions OR Medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death).
The overall number of participants who experienced any adverse event is reported. Grades are based on maximum severity per participant.</description>
        <time_frame>From the time of the first vaccination through 28 days after each vaccination (up to Day 126).</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>BBIBP bOPV Lot 1</title>
            <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 1, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>BBIBP bOPV Lot 2</title>
            <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 2, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
          <group group_id="O3">
            <title>BioFarma bOPV</title>
            <description>Infants received 2 drops of WHO prequalified liquid bivalent oral polio vaccine manufactured by BioFarma, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Adverse Events</title>
          <description>Adverse events were graded as mild (Grade 1 = No or minimal interference with usual activities; no medical intervention/therapy required), moderate (Grade 2 = Greater than minimal interference with usual activities; no or minimal medical intervention/therapy required), severe (Grade 3 = Marked limitation in ability to perform usual activities; medical intervention/therapy required), or potentially life-threatening (Grade 4 = Inability to perform basic functions OR Medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death).
The overall number of participants who experienced any adverse event is reported. Grades are based on maximum severity per participant.</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="250"/>
                <count group_id="O3" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="142"/>
                    <measurement group_id="O3" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="114"/>
                    <measurement group_id="O3" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-polio Neutralizing Antibody Geometric Mean Titers (GMT): Serotype 1</title>
        <description>The assays for determination of anti-poliovirus neutralizing antibodies at the National Institutes for Food and Drug Control (NIFDC) were validated.
Anti-polio antibody titer four weeks after the fourth vaccination was adjusted for the decrease in maternal antibodies based on a half-life of 28 days.</description>
        <time_frame>Screening and 4 weeks post vaccination 4 (Week 18)</time_frame>
        <population>Per Protocol Immunogenicity (PP-IMM) population includes all enrolled participants who were randomized, received all 4 doses of bOPV per the assigned treatment group, had post-vaccination immunogenicity measurement(s),and no major protocol violations that would have potentially interfered with the immunogenicity assessment of the study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>BBIBP bOPV Lot 1</title>
            <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 1, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>BBIBP bOPV Lot 2</title>
            <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 2, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
          <group group_id="O3">
            <title>BBIBP bOPV Lot 1 + Lot 2</title>
            <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 1 or Lot 2, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
          <group group_id="O4">
            <title>BioFarma bOPV</title>
            <description>Infants received 2 drops of WHO prequalified liquid bivalent oral polio vaccine manufactured by BioFarma, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-polio Neutralizing Antibody Geometric Mean Titers (GMT): Serotype 1</title>
          <description>The assays for determination of anti-poliovirus neutralizing antibodies at the National Institutes for Food and Drug Control (NIFDC) were validated.
Anti-polio antibody titer four weeks after the fourth vaccination was adjusted for the decrease in maternal antibodies based on a half-life of 28 days.</description>
          <population>Per Protocol Immunogenicity (PP-IMM) population includes all enrolled participants who were randomized, received all 4 doses of bOPV per the assigned treatment group, had post-vaccination immunogenicity measurement(s),and no major protocol violations that would have potentially interfered with the immunogenicity assessment of the study vaccine.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="217"/>
                <count group_id="O3" value="443"/>
                <count group_id="O4" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" lower_limit="33.7" upper_limit="49.7"/>
                    <measurement group_id="O2" value="41.5" lower_limit="34.0" upper_limit="50.6"/>
                    <measurement group_id="O3" value="41.2" lower_limit="35.9" upper_limit="47.3"/>
                    <measurement group_id="O4" value="47.7" lower_limit="38.4" upper_limit="59.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Weeks after vaccination 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55192" lower_limit="45821" upper_limit="66478"/>
                    <measurement group_id="O2" value="65790" lower_limit="55728" upper_limit="77668"/>
                    <measurement group_id="O3" value="60151" lower_limit="53095" upper_limit="68144"/>
                    <measurement group_id="O4" value="55634" lower_limit="46484" upper_limit="66586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Primary efficacy objective 1 of this study was to demonstrate the equivalence of two lots of BBIBP bOPV in terms of post-vaccination anti-polio neutralizing antibody GMTs. The immune response of the two lots of BBIBP bOPV would be declared equivalent if the 95% confidence interval (CI) for the serotype-specific GMT ratio for both serotypes was contained within (0.5, 2.0).</non_inferiority_desc>
            <param_type>Ratio of Geometric Mean Titers</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>Lot 1 / Lot 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Secondary efficacy objective 2 of this study was to demonstrate the non-inferiority of the two lots of BBIBP bOPV combined to the WHO control in terms of post-vaccination anti-polio neutralizing antibody GMTs. The two Lots combined would be declared non-inferior to the WHO control if the lower limit of the 95% CI for the serotype-specific GMT ratio of BBIBP Lots 1+2 over WHO control for both serotypes was &gt; 0.5.</non_inferiority_desc>
            <param_type>Ratio of Geometric Mean Titers</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
            <estimate_desc>Lot 1 + Lot 2 / BioFarma bOPV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-polio Neutralizing Antibody Geometric Mean Titers: Serotype 3</title>
        <description>The assays for determination of anti-poliovirus neutralizing antibodies at the National Institutes for Food and Drug Control (NIFDC) were validated.
Anti-polio antibody titer four weeks after the fourth vaccination was adjusted for the decrease in maternal antibodies based on a half-life of 28 days.</description>
        <time_frame>Screening and 4 weeks post vaccination 4 (Week 18)</time_frame>
        <population>Per Protocol Immunogenicity (PP-IMM) population</population>
        <group_list>
          <group group_id="O1">
            <title>BBIBP bOPV Lot 1</title>
            <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 1, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>BBIBP bOPV Lot 2</title>
            <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 2, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
          <group group_id="O3">
            <title>BBIBP bOPV Lot 1 + Lot 2</title>
            <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 1 or Lot 2, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
          <group group_id="O4">
            <title>BioFarma bOPV</title>
            <description>Infants received 2 drops of WHO prequalified liquid bivalent oral polio vaccine manufactured by BioFarma, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-polio Neutralizing Antibody Geometric Mean Titers: Serotype 3</title>
          <description>The assays for determination of anti-poliovirus neutralizing antibodies at the National Institutes for Food and Drug Control (NIFDC) were validated.
Anti-polio antibody titer four weeks after the fourth vaccination was adjusted for the decrease in maternal antibodies based on a half-life of 28 days.</description>
          <population>Per Protocol Immunogenicity (PP-IMM) population</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="217"/>
                <count group_id="O3" value="443"/>
                <count group_id="O4" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="10.7" upper_limit="14.6"/>
                    <measurement group_id="O2" value="15.6" lower_limit="12.8" upper_limit="19.0"/>
                    <measurement group_id="O3" value="13.9" lower_limit="12.3" upper_limit="15.8"/>
                    <measurement group_id="O4" value="14.3" lower_limit="12.0" upper_limit="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Weeks after vaccination 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11374" lower_limit="9686" upper_limit="13355"/>
                    <measurement group_id="O2" value="12390" lower_limit="10559" upper_limit="14539"/>
                    <measurement group_id="O3" value="11861" lower_limit="10594" upper_limit="13280"/>
                    <measurement group_id="O4" value="8063" lower_limit="6811" upper_limit="9545"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Primary efficacy objective 1 of this study was to demonstrate the equivalence of two lots of BBIBP bOPV in terms of post-vaccination anti-polio neutralizing antibody GMTs. The immune response of the two lots of BBIBP bOPV would be declared equivalent if the 95% confidence interval (CI) for the serotype-specific GMT ratio for both serotypes was contained within (0.5, 2.0).</non_inferiority_desc>
            <param_type>Ratio of Geometric Mean Titers</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
            <estimate_desc>Lot 1 / Lot 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Secondary efficacy objective 2 of this study was to demonstrate the non-inferiority of the two lots of BBIBP bOPV combined to the WHO control in terms of post-vaccination anti-polio neutralizing antibody GMTs. The two Lots combined would be declared non-inferior to the WHO control if the lower limit of the 95% CI for the serotype-specific GMT ratio of BBIBP Lots 1+2 over WHO control for both serotypes was &gt; 0.5.</non_inferiority_desc>
            <param_type>Ratio of Geometric Mean Titers</param_type>
            <param_value>1.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.21</ci_lower_limit>
            <ci_upper_limit>1.79</ci_upper_limit>
            <estimate_desc>BBIBP bOPV Lot 1 + Lot 2 / BioFarma bOPV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Infants With Serotype-specific Anti-polio Neutralizing Antibody Seroconversion 4 Weeks After Last Dose</title>
        <description>The assays for determination of anti-poliovirus neutralizing antibodies at the National Institutes for Food and Drug Control (NIFDC) were validated.
Seroconversion was defined as a titer ≥ 1:8 if seronegative at screening, otherwise a ≥ 4-fold increase in adjusted titers (i.e., adjusted for the decay in maternal antibodies, based on a half life of 28 days).</description>
        <time_frame>4 weeks post vaccination 4 (Week 18)</time_frame>
        <population>Per Protocol Immunogenicity (PP-IMM) population</population>
        <group_list>
          <group group_id="O1">
            <title>BBIBP bOPV Lot 1</title>
            <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 1, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>BBIBP bOPV Lot 2</title>
            <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 2, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
          <group group_id="O3">
            <title>BBIBP bOPV Lot 1 + Lot 2</title>
            <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 1 or Lot 2, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
          <group group_id="O4">
            <title>BioFarma bOPV</title>
            <description>Infants received 2 drops of WHO prequalified liquid bivalent oral polio vaccine manufactured by BioFarma, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Serotype-specific Anti-polio Neutralizing Antibody Seroconversion 4 Weeks After Last Dose</title>
          <description>The assays for determination of anti-poliovirus neutralizing antibodies at the National Institutes for Food and Drug Control (NIFDC) were validated.
Seroconversion was defined as a titer ≥ 1:8 if seronegative at screening, otherwise a ≥ 4-fold increase in adjusted titers (i.e., adjusted for the decay in maternal antibodies, based on a half life of 28 days).</description>
          <population>Per Protocol Immunogenicity (PP-IMM) population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="217"/>
                <count group_id="O3" value="443"/>
                <count group_id="O4" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223"/>
                    <measurement group_id="O2" value="215"/>
                    <measurement group_id="O3" value="438"/>
                    <measurement group_id="O4" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223"/>
                    <measurement group_id="O2" value="214"/>
                    <measurement group_id="O3" value="437"/>
                    <measurement group_id="O4" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For serotype 1</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Primary efficacy objective 2 of this study was to demonstrate the non-inferiority of the two lots of BBIBP bOPV combined to the WHO control in terms of post-vaccination anti-polio neutralizing antibody seroconversion rates. The immune response of the combined lots of BBIBP bOPV would be declared non-inferior to the WHO control if the lower limit of the 95% CI for the difference in percent responders is greater than negative 10, provided the two lots are declared equivalent.</non_inferiority_desc>
            <param_type>Difference in seroconversion rate</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>4.6</ci_upper_limit>
            <estimate_desc>BBIBP bOPV (Lot 1 + Lot 2) - BioFarma bOPV</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Serotype 3</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Primary efficacy objective 2 of this study was to demonstrate the non-inferiority of the two lots of BBIBP bOPV combined to the WHO control in terms of post-vaccination anti-polio neutralizing antibody seroconversion rates. The immune response of the combined lots of BBIBP bOPV would be declared non-inferior to the WHO control if the lower limit of the 95% CI for the difference in percent responders is greater than negative 10, provided the two lots are declared equivalent.</non_inferiority_desc>
            <param_type>Difference in seroconversion rate</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>5.6</ci_upper_limit>
            <estimate_desc>BBIBP bOPV (Lot 1 + Lot 2) - BioFarma bOPV</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Serotype 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Secondary efficacy objective 1 of this study was to show consistency of the two lots in terms of post-vaccination anti-polio neutralizing antibody seroconversion rates. The two lots would be declared consistent if the upper and lower limits of the 95% CI for the difference in seroconversion rates is within 10 percentage points of the observed difference for both serotypes.</non_inferiority_desc>
            <param_type>Difference in seroconversion rate</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.0</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
            <estimate_desc>Lot 1 - Lot 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Serotype 3</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Secondary efficacy objective 1 of this study was to show consistency of the two lots in terms of post-vaccination anti-polio neutralizing antibody seroconversion rates. The two lots would be declared consistent if the upper and lower limits of the 95% CI for the difference in seroconversion rates is within 10 percentage points of the observed difference for both serotypes.</non_inferiority_desc>
            <param_type>Difference in seroconversion rate</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.6</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
            <estimate_desc>Lot 1 - Lot 2</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-hepatitis B Surface Antigen (HBsAg) Geometric Mean Titers</title>
        <description>Anti-HBsAg titers were measured to assess the impact of concomitant administration of BBIBP liquid bOPV on immune responses to other Expanded Programme on Immunization (EPI) vaccines in comparison to that of the WHO pre-qualified bOPV, 4 weeks after the fourth vaccination.
The enzyme-linked immunosorbent assay (ELISA) assays for serum antibodies to HBsAg were performed at the Children's Hospital Medical Center (CCHMC). The HBsAb assay was a qualified assay using a kit from BioRad.</description>
        <time_frame>4 weeks post vaccination 4 (Week 18)</time_frame>
        <population>Participants who received all 4 bOPV vaccinations and ≥ 3 hepatitis B virus vaccinations at least 21 days prior to blood draw.</population>
        <group_list>
          <group group_id="O1">
            <title>BBIBP bOPV Lot 1</title>
            <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 1, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>BBIBP bOPV Lot 2</title>
            <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 2, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
          <group group_id="O3">
            <title>BBIBP bOPV Lot 1 + Lot 2</title>
            <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 1 or Lot 2, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
          <group group_id="O4">
            <title>BioFarma bOPV</title>
            <description>Infants received 2 drops of WHO prequalified liquid bivalent oral polio vaccine manufactured by BioFarma, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-hepatitis B Surface Antigen (HBsAg) Geometric Mean Titers</title>
          <description>Anti-HBsAg titers were measured to assess the impact of concomitant administration of BBIBP liquid bOPV on immune responses to other Expanded Programme on Immunization (EPI) vaccines in comparison to that of the WHO pre-qualified bOPV, 4 weeks after the fourth vaccination.
The enzyme-linked immunosorbent assay (ELISA) assays for serum antibodies to HBsAg were performed at the Children's Hospital Medical Center (CCHMC). The HBsAb assay was a qualified assay using a kit from BioRad.</description>
          <population>Participants who received all 4 bOPV vaccinations and ≥ 3 hepatitis B virus vaccinations at least 21 days prior to blood draw.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="203"/>
                <count group_id="O3" value="412"/>
                <count group_id="O4" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="320" lower_limit="246" upper_limit="416"/>
                    <measurement group_id="O2" value="322" lower_limit="255" upper_limit="407"/>
                    <measurement group_id="O3" value="321" lower_limit="269" upper_limit="383"/>
                    <measurement group_id="O4" value="267" lower_limit="207" upper_limit="345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>To show non-inferiority of Lots 1+2 combined versus BioFarma bOPV Control, the lower limit of the 95% CI must be &gt; 0.5.</non_inferiority_desc>
            <param_type>Ratio of Geometric Mean Titers</param_type>
            <param_value>1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.63</ci_upper_limit>
            <estimate_desc>Lot 1 + Lot 2 / BioFarma bOPV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants With Anti-hepatitis B Surface Antigen (HBsAg) Seroprotection</title>
        <description>Seroprotection was defined as a HBsAg titer ≥ 1:10 The ELISA assays for serum antibodies to HBsAg were performed at the Children's Hospital Medical Center (CCHMC). The HBsAb assay was a qualified assay using a kit from BioRad.</description>
        <time_frame>28 days after vaccination 4</time_frame>
        <population>Participants who received all 4 bOPV vaccinations and ≥ 3 hepatitis B virus vaccinations at least 21 days prior to blood draw.</population>
        <group_list>
          <group group_id="O1">
            <title>BBIBP bOPV Lot 1</title>
            <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 1, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>BBIBP bOPV Lot 2</title>
            <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 2, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
          <group group_id="O3">
            <title>BBIBP bOPV Lot 1 + Lot 2</title>
            <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 1 or Lot 2, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
          <group group_id="O4">
            <title>BioFarma bOPV</title>
            <description>Infants received 2 drops of WHO prequalified liquid bivalent oral polio vaccine manufactured by BioFarma, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Anti-hepatitis B Surface Antigen (HBsAg) Seroprotection</title>
          <description>Seroprotection was defined as a HBsAg titer ≥ 1:10 The ELISA assays for serum antibodies to HBsAg were performed at the Children's Hospital Medical Center (CCHMC). The HBsAb assay was a qualified assay using a kit from BioRad.</description>
          <population>Participants who received all 4 bOPV vaccinations and ≥ 3 hepatitis B virus vaccinations at least 21 days prior to blood draw.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="203"/>
                <count group_id="O3" value="412"/>
                <count group_id="O4" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192"/>
                    <measurement group_id="O2" value="194"/>
                    <measurement group_id="O3" value="386"/>
                    <measurement group_id="O4" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5586</p_value>
            <method>Fisher’s exact 1-tailed test</method>
            <method_desc>Fisher’s exact 1-tailed test of a lower rate in Lots 1+2</method_desc>
            <param_type>Difference in seroprotection rate</param_type>
            <param_value>-0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.86</ci_lower_limit>
            <ci_upper_limit>4.48</ci_upper_limit>
            <estimate_desc>BBIBP bOPV (Lot 1 + Lot 2) - BioFarma bOPV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-Rotavirus Immunoglobulin A (IgA) Geometric Mean Titers</title>
        <description>Anti-rotavirus immunoglobulin A titers were measured to assess the impact of concomitant administration of BBIBP liquid bOPV on immune responses to other Expanded Programme on Immunization (EPI) vaccines in comparison to that of the WHO pre-qualified bOPV, 4 weeks after the fourth vaccination.
The ELISA assay for antibodies to rotavirus was performed at the Children's Hospital Medical Center (CCHMC) using a validated in-house assay.</description>
        <time_frame>4 weeks post vaccination 4 (Week 18)</time_frame>
        <population>Participants who received all 4 bOPV vaccinations and ≥ 2 Rotavirus vaccinations at least 21 days prior to blood draw</population>
        <group_list>
          <group group_id="O1">
            <title>BBIBP bOPV Lot 1</title>
            <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 1, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>BBIBP bOPV Lot 2</title>
            <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 2, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
          <group group_id="O3">
            <title>BBIBP bOPV Lot 1 + Lot 2</title>
            <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 1 or Lot 2, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
          <group group_id="O4">
            <title>BioFarma bOPV</title>
            <description>Infants received 2 drops of WHO prequalified liquid bivalent oral polio vaccine manufactured by BioFarma, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-Rotavirus Immunoglobulin A (IgA) Geometric Mean Titers</title>
          <description>Anti-rotavirus immunoglobulin A titers were measured to assess the impact of concomitant administration of BBIBP liquid bOPV on immune responses to other Expanded Programme on Immunization (EPI) vaccines in comparison to that of the WHO pre-qualified bOPV, 4 weeks after the fourth vaccination.
The ELISA assay for antibodies to rotavirus was performed at the Children's Hospital Medical Center (CCHMC) using a validated in-house assay.</description>
          <population>Participants who received all 4 bOPV vaccinations and ≥ 2 Rotavirus vaccinations at least 21 days prior to blood draw</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="429"/>
                <count group_id="O4" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" lower_limit="17.6" upper_limit="29.6"/>
                    <measurement group_id="O2" value="35.8" lower_limit="26.8" upper_limit="47.8"/>
                    <measurement group_id="O3" value="28.3" lower_limit="23.3" upper_limit="34.2"/>
                    <measurement group_id="O4" value="28.6" lower_limit="21.5" upper_limit="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>To show non-inferiority of Lots 1+2 combined versus BioFarma bOPV Control, the lower limit of the 95% CI must be &gt; 0.5.</non_inferiority_desc>
            <param_type>Ratio of Geometric Mean Titers</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
            <estimate_desc>Lot 1 + Lot 2 / BioFarma bOPV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time of the first vaccination through completion of the study at 3 months after the last vaccination (Day 182) for serious adverse events and through 28 days after each vaccination (up to Day 126) for non-serious adverse events.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BBIBP bOPV Lot 1</title>
          <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 1, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
        </group>
        <group group_id="E2">
          <title>BBIBP bOPV Lot 2</title>
          <description>Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 2, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
        </group>
        <group group_id="E3">
          <title>BioFarma bOPV</title>
          <description>Infants received 2 drops of WHO prequalified liquid bivalent oral polio vaccine manufactured by BioFarma, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (Unspecified)">Anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Breast abcess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Pyomyositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Sepsis neonatal</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Herbal toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Jaundice neonatal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="143" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="142" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="151" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (Unspecified)">Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Ankyloglossia congenital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Laryngomalacia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Talipes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Anal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Dyschezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Gingival discolouration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Gingival disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Gingival pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Infantile colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Mucous stools</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abscess sterile</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Developmental delay</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Granuloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Irritability postvaccinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Vaccination site pain (for other EPI vaccines)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (Unspecified)">Vaccination site swelling (for other EPI vaccines)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Dysentery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Eczema infected</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Eye infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Myiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Omphalitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Ophthalmia neonatorum</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Sepsis neonatal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Septic rash</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Tinea capitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Tinea faciei</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (Unspecified)">Tinea infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Umbilical sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="100" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (Unspecified)">Adverse event following immunisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Poor feeding infant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Jaundice neonatal</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Umbilical cord abnormality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Umbilical cord haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Umbilical granuloma</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Nasal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dandruff</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Dermatitis bullous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Eczema infantile</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (Unspecified)">Exfoliative rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Milia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Miliaria</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Umbilical haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Vitiligo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jorge Flores</name_or_title>
      <organization>PATH</organization>
      <phone>(202) 822-0033</phone>
      <email>jeflores@path.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

